However, its approval has been met with controversy due to debates over its clinical efficacy and associated risks. Donanemab, developed by Eli Lilly, is another promising monoclonal antibody ...

Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder affecting millions of people worldwide. AD has a multifactorial origin, resulting from an ...

A third agent in the class, donanemab (Kisunla), gained FDA approval ... microglia to ingest and eliminate fibrillar amyloid-beta (Aβ), according to a review in BioDrugs. "Each of the approved ...

Understanding how long a person can stay independent may help some people and clinicians determine if trying a drug such as lecanemab or donanemab is worth the risks and high prices. The study ...

New research shows that lecanemab and donanemab can slow cognitive decline ... samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical and cognitive ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...

In mouse models, they found that the CSF Aβ42/40 ratio corresponded more closely to Aβ protofibrils in the brain than to ... But why does the Aβ42/40 ratio rise during donanemab treatment, when this ...

But while the approvals of lecanemab and donanemab, both antibody therapies that clear plaque-causing amyloid proteins from the brain, were greeted with enthusiasm by some Alzheimer's researchers ...